Federated Hermes Inc. Sells 9,387 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Federated Hermes Inc. lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.8% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 236,200 shares of the biopharmaceutical company’s stock after selling 9,387 shares during the period. Federated Hermes Inc.’s holdings in Regeneron Pharmaceuticals were worth $132,808,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC increased its stake in shares of Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 686 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at approximately $226,000. Patton Fund Management Inc. bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $210,000. Avior Wealth Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 66.0% during the second quarter. Avior Wealth Management LLC now owns 1,461 shares of the biopharmaceutical company’s stock worth $767,000 after buying an additional 581 shares during the last quarter. Finally, Independence Bank of Kentucky lifted its holdings in shares of Regeneron Pharmaceuticals by 23.8% during the second quarter. Independence Bank of Kentucky now owns 286 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 55 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Canaccord Genuity Group raised their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Evercore ISI increased their price target on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a report on Thursday, January 22nd. Hsbc Global Res upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 24th. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday, December 29th. Finally, UBS Group increased their target price on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $784.77.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $771.25 on Wednesday. The company has a 50-day moving average of $757.47 and a 200-day moving average of $647.23. The company has a market capitalization of $81.06 billion, a price-to-earnings ratio of 18.47, a PEG ratio of 1.99 and a beta of 0.39. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.33 and a current ratio of 4.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. During the same quarter in the previous year, the firm posted $12.46 earnings per share. The firm’s revenue for the quarter was up .9% on a year-over-year basis. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the sale, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. The trade was a 46.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares in the company, valued at $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.